What is Immune Technology?
Immune Technology Corp. is a specialized biotechnology firm dedicated to supplying a comprehensive suite of immunological products. Their offerings include primary antibodies, bacterial and viral antigens, tumor markers, and ELISA kits. Complementing their product catalog, the company provides bespoke services such as plasmid production, polyclonal antibody generation, and protein synthesis, catering to the specific requirements of clients in research institutions and healthcare organizations. Their focus on immunology and pathogen research is underscored by a strong commitment to quality, evidenced by their ISO 9001:2015 certification.
How much funding has Immune Technology raised?
Immune Technology has raised a total of $48K across 1 funding round:
Debt
$48K
Debt (2021): $48K with participation from PPP
Key Investors in Immune Technology
PPP
Public-Private Partnership
What's next for Immune Technology?
With the recent influx of substantial expansion capital, Immune Technology is poised for accelerated growth and enhanced operational capacity. This strategic financing, occurring at a significant Series B/C stage, suggests a focus on scaling production, expanding research and development initiatives, and potentially broadening market reach. The company's established expertise in biotechnology products and custom services, coupled with its quality certifications, positions it favorably to leverage this investment for further innovation and market penetration in the immunology and healthcare sectors.
See full Immune Technology company page
